Rhythm Pharmaceuticals Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
283
- Stock Symbol
-
RYTM
- Investments
-
1
- Share Price
-
$54.30
- (As of Wednesday Closing)
Rhythm Pharmaceuticals General Information
Description
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Contact Information
Website
www.rhythmtx.comCorporate Office
- 222 Berkeley Street
- 12th Floor
- Boston, MA 02116
- United States
Corporate Office
- 222 Berkeley Street
- 12th Floor
- Boston, MA 02116
- United States
Rhythm Pharmaceuticals Timeline
Rhythm Pharmaceuticals Stock Performance
As of 26-Mar-2025, Rhythm Pharmaceuticals’s stock price is $54.30. Its current market cap is $3.43B with 63.2M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $54.30 | $52.91 | $35.17 - $68.58 | $3.43B | 63.2M | 509K | -$4.34 |
Rhythm Pharmaceuticals Financials Summary
As of 31-Dec-2024, Rhythm Pharmaceuticals has a trailing 12-month revenue of $130M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 3,287,488 | 3,287,488 | 2,418,844 | 1,295,172 |
| Revenue | 130,126 | 130,126 | 77,428 | 23,638 |
| EBITDA | (252,801) | (252,801) | (182,409) | (178,275) |
| Net Income | (260,602) | (260,602) | (184,678) | (181,119) |
| Total Assets | 392,273 | 392,273 | 332,745 | 382,481 |
| Total Debt | 3,938 | 3,938 | 1,260 | 1,944 |
Rhythm Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Rhythm Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Rhythm Pharmaceuticals Comparisons
Industry
Financing
Details
Rhythm Pharmaceuticals Competitors (46)
One of Rhythm Pharmaceuticals’s 46 competitors is Rein Therapeutics, a Formerly VC-backed company based in Austin, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Rhythm Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Rhythm Pharmaceuticals Patents
Rhythm Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023308310-A1 | Methods for treating obesity with an mc4r agonist | Pending | 12-Jul-2022 | ||
| AU-2021350017-A1 | Methods of treating melanocortin-4 receptor pathway-associated disorders | Pending | 24-Sep-2020 | ||
| EP-4216979-A1 | Methods of treating melanocortin-4 receptor pathway-associated disorders | Pending | 24-Sep-2020 | ||
| CA-3192873-A1 | Methods of treating melanocortin-4 receptor pathway-associated disorders | Pending | 24-Sep-2020 | ||
| US-20240058414-A1 | Methods of treating melanocortin-4 receptor pathway-associated disorders | Pending | 24-Sep-2020 | A61K38/12 |
Rhythm Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Rhythm Pharmaceuticals Investments (1)
Rhythm Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Takeda Pharmaceutical Company (Rights of RM-853 Therapy for Prader-Willi Syndrome). The deal was made on 02-Apr-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Takeda Pharmaceutical Company (Rights of RM-853 Therapy for Prader-Willi Syndrome) | 02-Apr-2018 | Corporate Asset Purchase | Buildings and Property |
Rhythm Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated December, 06, 2022
25.74 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Rhythm Pharmaceuticals FAQs
-
When was Rhythm Pharmaceuticals founded?
Rhythm Pharmaceuticals was founded in 2008.
-
Where is Rhythm Pharmaceuticals headquartered?
Rhythm Pharmaceuticals is headquartered in Boston, MA.
-
What is the size of Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals has 283 total employees.
-
What industry is Rhythm Pharmaceuticals in?
Rhythm Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Rhythm Pharmaceuticals a private or public company?
Rhythm Pharmaceuticals is a Public company.
-
What is Rhythm Pharmaceuticals’s stock symbol?
The ticker symbol for Rhythm Pharmaceuticals is RYTM.
-
What is the current stock price of Rhythm Pharmaceuticals?
As of 26-Mar-2025 the stock price of Rhythm Pharmaceuticals is $54.30.
-
What is the current market cap of Rhythm Pharmaceuticals?
The current market capitalization of Rhythm Pharmaceuticals is $3.43B.
-
What is Rhythm Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Rhythm Pharmaceuticals is $130M.
-
Who are Rhythm Pharmaceuticals’s competitors?
Rein Therapeutics, NexImmune, Mesoblast, Regulus Therapeutics, and Alnylam Pharmaceuticals are some of the 46 competitors of Rhythm Pharmaceuticals.
-
What is Rhythm Pharmaceuticals’s annual earnings per share (EPS)?
Rhythm Pharmaceuticals’s EPS for 12 months was -$4.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
